Skip to Main Content

Paper Details

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge.
N Engl J Med
173
2022
Author NameAffiliation
Ran D Balicerand the Clalit Research Institute, Clalit Health Services, Sapir College, Jerusalem College of Technology, Israel Institute of Technology, and the School of Public Health, Ben-Gurion University of the Negev, Harvard Medical School and Clalit Research Institute (N.D., Harvard Medical School (N.D.) - both in Boston.
  • 1 - 1

Datasets